BR112015030685A2 - método para diferenciar células-tronco, células, biobanco de células, uso das células e composição terapêutica - Google Patents

método para diferenciar células-tronco, células, biobanco de células, uso das células e composição terapêutica

Info

Publication number
BR112015030685A2
BR112015030685A2 BR112015030685A BR112015030685A BR112015030685A2 BR 112015030685 A2 BR112015030685 A2 BR 112015030685A2 BR 112015030685 A BR112015030685 A BR 112015030685A BR 112015030685 A BR112015030685 A BR 112015030685A BR 112015030685 A2 BR112015030685 A2 BR 112015030685A2
Authority
BR
Brazil
Prior art keywords
cells
cell
stem cells
biobank
differentiating
Prior art date
Application number
BR112015030685A
Other languages
English (en)
Inventor
Patsch Christoph
Bailly Jacques
Graf Martin
Ciampi Osele
Iacone Roberto
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015030685A2 publication Critical patent/BR112015030685A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0687—Renal stem cells; Renal progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

resumo “método para diferenciar células-tronco, células, biobanco de células, uso das células e composição terapêutica” esse pedido refere-se a um método para diferenciar células-tronco pluripotentes (pscs) em células precursoras renais multicompetentes que expressam six2. essas células precursoras renais são capazes de se diferenciar em podócitos totalmente funcionais e totalmente diferenciados. além disso, esse pedido refere-se a um método para diferenciar células-tronco embrionárias humanas (escs) e células-tronco pluripotentes induzidas (ipscs) em células precursoras renais definidas que expressam six2 e podócitos, com base nas etapas ligadas de induções de meio definido quimicamente.
BR112015030685A 2013-07-29 2014-07-25 método para diferenciar células-tronco, células, biobanco de células, uso das células e composição terapêutica BR112015030685A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13178342 2013-07-29
PCT/EP2014/065991 WO2015014731A1 (en) 2013-07-29 2014-07-25 Method for differentiation of pluripotent stem cells into multi-competent renal precursors

Publications (1)

Publication Number Publication Date
BR112015030685A2 true BR112015030685A2 (pt) 2017-07-25

Family

ID=48874919

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030685A BR112015030685A2 (pt) 2013-07-29 2014-07-25 método para diferenciar células-tronco, células, biobanco de células, uso das células e composição terapêutica

Country Status (11)

Country Link
US (1) US10138468B2 (pt)
EP (1) EP3027737B1 (pt)
JP (1) JP6440711B2 (pt)
KR (1) KR20160034323A (pt)
CN (1) CN105339489B (pt)
BR (1) BR112015030685A2 (pt)
CA (1) CA2914479A1 (pt)
HK (1) HK1221487A1 (pt)
MX (1) MX2015017330A (pt)
RU (1) RU2016106953A (pt)
WO (1) WO2015014731A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2968655C (en) 2014-11-25 2021-11-16 President And Fellows Of Harvard College Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
ES2897974T3 (es) 2015-09-11 2022-03-03 Astellas Pharma Inc Método para producir células progenitoras renales
WO2017049243A1 (en) * 2015-09-17 2017-03-23 Bonventre Joseph V Methods of generating nephrons from human pluripotent stem cells
CN106754649A (zh) * 2017-02-16 2017-05-31 中国人民解放军总医院 利用人多能干细胞构建类肾器官的培养方法
WO2019230737A1 (ja) * 2018-05-29 2019-12-05 国立大学法人熊本大学 糸球体ポドサイトの誘導方法、及び該誘導方法を用いた多能性幹細胞からのポドサイトの製造方法
KR102150489B1 (ko) * 2019-04-09 2020-09-01 고려대학교 산학협력단 소변세포로부터 신장전구세포로의 직접 역분화를 유도하는 방법 및 이의 방법으로 역분화된 신장전구세포를 포함하는 신장세포 손상 질환 예방 또는 치료용 약학 조성물
CN110522902B (zh) * 2019-09-25 2022-10-11 南京农业大学 一种用于建立慢性肾病模型的组合物及其应用
KR20230147033A (ko) * 2020-11-13 2023-10-20 티모시 에이. 버트람 풍부화된 생체활성 신장 세포 집단, 그의 특징 및 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0505970D0 (en) * 2005-03-23 2005-04-27 Univ Edinburgh Culture medium containing kinase inhibitor, and uses thereof
US20070031966A1 (en) * 2005-07-18 2007-02-08 Regents Of The University Of Michigan Renal progenitor cells from embryonic stem cells
JP5896360B2 (ja) * 2010-07-21 2016-04-13 国立大学法人京都大学 ヒト多能性幹細胞から中間中胚葉細胞への分化誘導方法
EP2718425B1 (en) * 2011-06-09 2017-05-10 F. Hoffmann-La Roche AG Method for differentiation of pluripotent stem cells into vascular bed cells
EP2794860B1 (en) * 2011-12-19 2017-05-03 Kyoto University Method for inducing differentiation of human pluripotent stem cells into intermediate mesoderm cells
AU2014279065B2 (en) * 2013-06-11 2020-04-09 Astellas Pharma Inc. Method for producing renal precursor cells, and drug containing renal precursor cells
AU2014280843B2 (en) * 2013-06-14 2017-04-20 The University Of Queensland Renal progenitor cells

Also Published As

Publication number Publication date
KR20160034323A (ko) 2016-03-29
CA2914479A1 (en) 2015-02-05
WO2015014731A1 (en) 2015-02-05
CN105339489A (zh) 2016-02-17
EP3027737B1 (en) 2018-12-26
US20160145578A1 (en) 2016-05-26
US10138468B2 (en) 2018-11-27
MX2015017330A (es) 2016-04-06
RU2016106953A (ru) 2017-08-31
EP3027737A1 (en) 2016-06-08
RU2016106953A3 (pt) 2018-03-30
HK1221487A1 (zh) 2017-06-02
JP2016529891A (ja) 2016-09-29
JP6440711B2 (ja) 2018-12-19
CN105339489B (zh) 2021-09-03

Similar Documents

Publication Publication Date Title
BR112015030685A2 (pt) método para diferenciar células-tronco, células, biobanco de células, uso das células e composição terapêutica
CL2020002805A1 (es) Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)
TN2015000050A1 (en) Methods of treating a tauopathy
TR201904270T4 (tr) Tanımlı koşullar altında insan pluripotent kök hücrelerinin hematoendotelyal farklılaşması için yöntemler ve materyaller.
SG10201906304TA (en) Use of perfusion decellularized liver for islet cell recellularization
PH12016500782A1 (en) Suspension and clustering of human pluripotent stem cells for differentation into pancreatic endocrine cells
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
WO2014153115A3 (en) Compositions and methods for reprogramming hematopoietic stem cell lineages
BR112015022536A2 (pt) pilha soec com aquecedor integrado
BR112014031424A2 (pt) tratamento de células pluripotentes
EP3070163A4 (en) Method for preparing induced pluripotent stem cell, composition used in method, and uses thereof
CL2015003599A1 (es) Solucion que contiene theralosa y dextrano para transplantar celulas de mamiferos
MX2021008627A (es) Medio de cultivo celular libre de suero.
MY197129A (en) Electrochemical coupling of two phenols which differ in their oxidation potential
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
BR112015021189A2 (pt) métodos de banco de células de alta densidade
EA201690718A1 (ru) Способ обработки целлюлозосодержащей биомассы
WO2014018785A3 (en) Biorefinery control system, components therefor, and methods of use
BR112016023818A2 (pt) método para a diferenciação das células estaminais pluripotentes em cardiomiócitos, cardiomiócitos, biobanco de cardiomiócitos, utilização dos cardiomiócitos composição terapêutica e métodos e utilizações
WO2013173714A3 (en) Conversion of cardiomyocytes into fast conducting cardiomyocytes or slow conducting nodal cells
BR112016021739A2 (pt) Método para preparar um poloxâmero para uso em um meio de cultura de célula
PT2571515T (pt) Processos e ensaios para tratar indivíduos com eliminação, mutação ou expressão reduzida de shank3
SG11201507844RA (en) Diffusion medium for use in fuel cell, fuel cell and method of making the diffusion medium
IN2014DN05638A (pt)
鈴木晃志郎 Preface for a Better Understanding of Environmental Conflict over the Renewable Energy Facility-Siting

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]